These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3480399)

  • 1. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
    Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
    Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
    Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
    Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
    Robert J; Rigal-Huguet F; Hurteloup P
    Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
    Eksborg S; Björkholm M; Hast R; Fagerlund E
    Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
    Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
    Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
    Tamassia V; Pacciarini MA; Moro E; Piazza E; Vago G; Libretti A
    Int J Clin Pharmacol Res; 1987; 7(5):419-26. PubMed ID: 3478310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
    Gillies HC; Herriott D; Liang R; Ohashi K; Rogers HJ; Harper PG
    Br J Clin Pharmacol; 1987 Mar; 23(3):303-10. PubMed ID: 3471265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
    Tidefelt U; Sundman-Engberg B; Paul C
    Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
    Ganzina F; Pacciarini MA; Di Pietro N
    Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
    Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
    Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
    Hempel G; Haberland S; Schulze-Westhoff P; Möhling N; Blaschke G; Boos J
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):287-92. PubMed ID: 9367219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
    Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
    Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
    Looby M; Linke R; Weiss M
    Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of idarubicin.
    Robert J
    Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
    Kuffel MJ; Reid JM; Ames MM
    Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.